Session

PP 05 IBD (Posters)

CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY
CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY

PP 05 IBD (Posters)  et al.

MRI FACTORS ASSOCIATED WITH RELAPSE FOLLOWING DISCONTINUATION OF BIOLOGIC MEDICATION IN CROHN’S DISEASE
MRI FACTORS ASSOCIATED WITH RELAPSE FOLLOWING DISCONTINUATION OF BIOLOGIC MEDICATION IN CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT
LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

PP 05 IBD (Posters)  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY
THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY

PP 05 IBD (Posters)  et al.

PAEDIATRIC INFLAMMATORY BOWEL DISEASE UNCLASSIFIED IN SCOTLAND: LONG-TERM LONGITUDINAL NATURAL HISTORY DATA WITH UP TO 20 YEARS OF FOLLOW-UP
PAEDIATRIC INFLAMMATORY BOWEL DISEASE UNCLASSIFIED IN SCOTLAND: LONG-TERM LONGITUDINAL NATURAL HISTORY DATA WITH UP TO 20 YEARS OF FOLLOW-UP

PP 05 IBD (Posters)  et al.

PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE
PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE

PP 05 IBD (Posters)  et al.

THE EFFECT OF COGNITIVE BEHAVIORAL THERAPY IN ADULTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF COGNITIVE BEHAVIORAL THERAPY IN ADULTS WITH INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

IN PATIENTS WITH CROHN'S DISEASE MONITORING OF USTEKINUMAB LEVELS DURING INDUCTION CAN IDENTIFY EARLY INADEQUATE RESPONSE
IN PATIENTS WITH CROHN'S DISEASE MONITORING OF USTEKINUMAB LEVELS DURING INDUCTION CAN IDENTIFY EARLY INADEQUATE RESPONSE

PP 05 IBD (Posters)  et al.

MIG (CXCL9) CHEMOKINE IS A KEY BIOMARKER THAT DISCRIMINATES BETWEEN PEDIATRIC IBD PATIENTS AND NON-IBD PATIENTS IN A NOVEL BIOMARKER MODEL
MIG (CXCL9) CHEMOKINE IS A KEY BIOMARKER THAT DISCRIMINATES BETWEEN PEDIATRIC IBD PATIENTS AND NON-IBD PATIENTS IN A NOVEL BIOMARKER MODEL

PP 05 IBD (Posters)  et al.

DOUBLE-EDGED SWORD EFFECT OF GLUCOCORTICOIDS IN EXPERIMENTAL COLITIS – IS THERE A ROLE OF RAPAMYCIN?
DOUBLE-EDGED SWORD EFFECT OF GLUCOCORTICOIDS IN EXPERIMENTAL COLITIS – IS THERE A ROLE OF RAPAMYCIN?

PP 05 IBD (Posters)  et al.

OVEREXPRESSION OF MIR-376A-3P IN CIRCULATING EXOSOMES IN PERIPHERAL BLOOD OF PATIENTS WITH CROHN'S DISEASE
OVEREXPRESSION OF MIR-376A-3P IN CIRCULATING EXOSOMES IN PERIPHERAL BLOOD OF PATIENTS WITH CROHN'S DISEASE

PP 05 IBD (Posters)  et al.

IBDQ AND NON-INVASIVE MACHINE LEARNING-BASED PREDICTION OF ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS
IBDQ AND NON-INVASIVE MACHINE LEARNING-BASED PREDICTION OF ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

HIGH PROPORTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE GERMAN COHORT OF THE IBD PODCAST STUDY
HIGH PROPORTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE GERMAN COHORT OF THE IBD PODCAST STUDY

PP 05 IBD (Posters)  et al.

PROTEIN FINGERPRINT ASSAYS REFLECTING NEUTROPHIL ACTIVITY, MUCOSAL DAMAGE, AND TISSUE FIBROSIS ARE SURROGATE BIOMARKERS FOR MUCOSAL HEALING IN PEDIATRIC CROHN’S DISEASE
PROTEIN FINGERPRINT ASSAYS REFLECTING NEUTROPHIL ACTIVITY, MUCOSAL DAMAGE, AND TISSUE FIBROSIS ARE SURROGATE BIOMARKERS FOR MUCOSAL HEALING IN PEDIATRIC CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

PREDICTIVE TRANSCRIPTIONAL SIGNATURES ASSOCIATED TO VEDOLIZUMAB THERAPY RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS
PREDICTIVE TRANSCRIPTIONAL SIGNATURES ASSOCIATED TO VEDOLIZUMAB THERAPY RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

UNCONTROLLED DEPRESSION AND FEMALE GENDER INCREASES THE RISK OF SEVERE FATIGUE MORE THAN ACTIVITY DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER INFLIXIMAB THERAPY
UNCONTROLLED DEPRESSION AND FEMALE GENDER INCREASES THE RISK OF SEVERE FATIGUE MORE THAN ACTIVITY DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER INFLIXIMAB THERAPY

PP 05 IBD (Posters)  et al.

COMBINATION THERAPY WITH BIOLOGICS AND SMALL MOLECULES IN REFRACTORY INFLAMMATORY BOWEL DISEASE (IBD): A SINGLE TERTIARY-CENTRE EXPERIENCE
COMBINATION THERAPY WITH BIOLOGICS AND SMALL MOLECULES IN REFRACTORY INFLAMMATORY BOWEL DISEASE (IBD): A SINGLE TERTIARY-CENTRE EXPERIENCE

PP 05 IBD (Posters)  et al.

EFFECTIVENESS AND SAFETY OUTCOMES AFTER LONG-TERM (54 WEEKS) VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE: A PROSPECTIVE, REAL-WORLD OBSERVATIONAL STUDY INCLUDING PATIENT-REPORTED OUTCOMES (POLONEZ II)
EFFECTIVENESS AND SAFETY OUTCOMES AFTER LONG-TERM (54 WEEKS) VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE: A PROSPECTIVE, REAL-WORLD OBSERVATIONAL STUDY INCLUDING PATIENT-REPORTED OUTCOMES (POLONEZ II)

PP 05 IBD (Posters)  et al.

BIOELECTRICAL IMPEDANCE ANALYSIS AND HEMATOLOGICAL SCALES - A BRAND NEW COMBINATION FOR THE EVALUATION OF IBD PATIENTS?
BIOELECTRICAL IMPEDANCE ANALYSIS AND HEMATOLOGICAL SCALES - A BRAND NEW COMBINATION FOR THE EVALUATION OF IBD PATIENTS?

PP 05 IBD (Posters)  et al.

Item 61 - 80 / 826
1 2 3
4
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42